We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+72.19%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$1.15B
AUM Growth
+$416M
Cap. Flow
+$154M
Cap. Flow %
13.42%
Top 10 Hldgs %
42.31%
Holding
115
New
23
Increased
29
Reduced
19
Closed
19

Top Buys

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$54.2M
2
APGE icon
Apogee Therapeutics
APGE
+$18.4M
3
ABVX
Abivax
ABVX
+$15.9M
4
SLNO
Soleno Therapeutics
SLNO
+$14.8M
5
CYTK icon
Cytokinetics
CYTK
+$14.4M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$32M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$12.5M
3
TVTX icon
Travere Therapeutics
TVTX
+$8.84M
4
INZY
Inozyme Pharma
INZY
+$7M
5
VERA icon
Vera Therapeutics
VERA
+$5.59M

Sector Composition

Rank Sector Weight
1 Healthcare 85.26%
2 Financials 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATYR
76
PUT
aTyr Pharma
ATYR
$47.7M
$1.51M 0.13%
+2,100,000
New +$9.52M
MIST icon
77
Milestone Pharmaceuticals
MIST
$147M
$1.33M 0.12%
+666,666
New +$1.17M
CMPS
78
Compass Pathways
CMPS
$1.57B
$1.15M 0.1%
+200,000
New +$899K
NXTC icon
79
NextCure
NXTC
$22M
$1.12M 0.1%
191,882
-1
-0% -$5
KPTI icon
80
CALL
Karyopharm Therapeutics
KPTI
$169M
$1.03M 0.09%
157,600
+100
+0.1% +$538
CATX icon
81
Perspective Therapeutics
CATX
$333M
$1.03M 0.09%
300,000
-750,000
-71% -$2.73M
ABUS icon
82
CALL
Arbutus Biopharma
ABUS
$871M
$960K 0.08%
211,500
+202,200
+2,174% +$743K
STRO icon
83
Sutro Biopharma
STRO
$374M
$654K 0.06%
75,272
– –
JBIO
84
Jade Biosciences
JBIO
$1.2B
$564K 0.05%
65,317
– –
ENGN icon
85
enGene Therapeutics
ENGN
$125M
$526K 0.05%
77,000
– –
CNTX icon
86
Context Therapeutics
CNTX
$56.6M
$390K 0.03%
402,653
-115,372
-22% -$93.5K
RPTX
87
DELISTED
Repare Therapeutics
RPTX
$352K 0.03%
200,000
– –
CBIO
88
Crescent Biopharma
CBIO
$537M
$214K 0.02%
17,998
-262,033
-94% -$3.48M
ADGM
89
Adagio Medical Holdings
ADGM
$11.3M
$155K 0.01%
80,000
– –
QTTB icon
90
Q32 Bio
QTTB
$346M
$55K ﹤0.01%
27,777
– –
SPRY icon
91
ARS Pharmaceuticals
SPRY
$640M
$25.1K ﹤0.01%
+2,500
New +$35.9K
RCKTW icon
92
Rocket Pharmaceuticals Warrant
RCKTW
$320K
$2.99K ﹤0.01%
75,000
– –
ALT icon
93
CALL
Altimmune
ALT
$546M
– –
-200,000
Closed -$774K
AMGN icon
94
CALL
Amgen
AMGN
$197B
– –
-40,000
Closed -$11.2M
APGE icon
95
PUT
Apogee Therapeutics
APGE
$10.1B
– –
-2,500
Closed -$109K
AXSM icon
96
Axsome Therapeutics
AXSM
$11.4B
– –
-50,000
Closed -$5.22M
BPMC
97
DELISTED
Blueprint Medicines
BPMC
– –
-250,000
Closed -$32M
CAPR icon
98
PUT
Capricor Therapeutics
CAPR
$1.13B
– –
-175,000
Closed -$1.74M
CRSP icon
99
CALL
CRISPR Therapeutics
CRSP
$4.63B
– –
-200,000
Closed -$9.73M
GALT icon
100
PUT
Galectin Therapeutics
GALT
$263M
– –
-250,000
Closed -$528K
1 2 3
4
5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q3 2025 Portfolio in Review

As of Q3 2025, Affinity Asset Advisors held 115 positions worth $1.15B, up 57% from $732M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Affinity Asset Advisors deployed $154M of net new capital in Q3 2025, opening 23 new positions and adding to 29 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 84,490 shares worth $56.3M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 88% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $12.5M trimmed.

  • Affinity Asset Advisors's largest Q3 2025 buy was State Street SPDR S&P 500 ETF Trust: 84,490 shares worth $56.3M.
  • Affinity Asset Advisors added most to Apogee Therapeutics in Q3 2025, an estimated $18.4M increase.
  • Affinity Asset Advisors's biggest Q3 2025 reduction was Protagonist Therapeutics, cutting an estimated $12.5M.
  • Affinity Asset Advisors fully exited Blueprint Medicines in Q3 2025, selling an estimated $32M.
  • Affinity Asset Advisors's ten largest holdings make up 42% of its $1.15B portfolio in Q3 2025.
  • Affinity Asset Advisors opened 23 new positions and closed 19 in Q3 2025.
  • Affinity Asset Advisors's portfolio value rose 57% quarter-over-quarter to $1.15B.

Based on Affinity Asset Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.